Birth prevalence of phenylalanine hydroxylase deficiency: a systematic literature review and meta-analysis
Related Experiment Video
Updated: Nov 3, 2025

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
Pamela K Foreman1, Andrea V Margulis2, Kimberly Alexander1
1BioMarin Pharmaceutical Inc, 770 Lindaro Street, San Rafael, CA, 94901, USA.
Insights
Phenylalanine hydroxylase (PAH) deficiency, an autosomal recessive disorder, has a global birth prevalence of 0.64 per 10,000 births. Significant regional variations exist, highlighting the need for tailored newborn screening strategies for this condition.
Area of Science:
- Genetics and Genetic Disorders
- Metabolic Disorders
- Public Health and Epidemiology
Background:
- Phenylalanine hydroxylase (PAH) deficiency is an inherited metabolic disorder causing elevated blood phenylalanine (Phe) levels.
- Untreated PAH deficiency can lead to severe neurocognitive impairment.
- Newborn screening is crucial for early detection and management of PAH deficiency.
Purpose of the Study:
- To estimate the global birth prevalence of PAH deficiency using newborn screening data.
- To analyze regional variations in PAH deficiency prevalence.
- To assess prevalence based on different phenylalanine (Phe) cutoff values used in confirmatory testing.
Main Methods:
- Systematic literature review and meta-analysis of newborn screening studies.
- Searches conducted in PubMed and Embase databases.
- Inclusion of studies reporting numeric birth prevalence of confirmed PAH deficiency.
Main Results:
- A global birth prevalence of 0.64 per 10,000 births was estimated (95% CI 0.53-0.75).
- Prevalence varied significantly by region, from 0.03 in Southeast Asia to 1.18 in the Middle East/North Africa.
- Prevalence estimates differed based on Phe cutoff values: 0.96 (360 µmol/L), 0.50 (600 µmol/L), and 0.30 (1200 µmol/L).
Conclusions:
- Substantial regional disparities in PAH deficiency birth prevalence were identified.
- The precision of prevalence estimates is constrained by sample sizes, even with widespread newborn screening.
- Further research may be needed to refine prevalence estimates and understand regional variations.
Background:
Phenylalanine hydroxylase (PAH) deficiency is an autosomal recessive disorder that results in elevated concentrations of phenylalanine (Phe) in the blood. If left untreated, the accumulation of Phe can result in profound neurocognitive disability. The objective of this systematic literature review and meta-analysis was to estimate the global birth prevalence of PAH deficiency from newborn screening studies and to estimate regional differences, overall and for various clinically relevant Phe cutoff values used in confirmatory testing.
Methods:
The protocol for this literature review was registered with PROSPERO (International prospective register of systematic reviews). Pubmed and Embase database searches were used to identify studies that reported the birth prevalence of PAH deficiency. Only studies including numeric birth prevalence reports of confirmed PAH deficiency were included.
Results:
From the 85 publications included in the review, 238 birth prevalence estimates were extracted. After excluding prevalence estimates that did not meet quality assessment criteria or because of temporal and regional overlap, estimates from 45 publications were included in the meta-analysis. The global birth prevalence of PAH deficiency, estimated by weighting regional birth prevalences relative to their share of the population of all regions included in the study, was 0.64 (95% confidence interval [CI] 0.53-0.75) per 10,000 births and ranged from 0.03 (95% CI 0.02-0.05) per 10,000 births in Southeast Asia to 1.18 (95% CI 0.64-1.87) per 10,000 births in the Middle East/North Africa. Regionally weighted global birth prevalences per 10,000 births by confirmatory test Phe cutoff values were 0.96 (95% CI 0.50-1.42) for the Phe cutoff value of 360 ± 100 µmol/L; 0.50 (95% CI 0.37-0.64) for the Phe cutoff value of 600 ± 100 µmol/L; and 0.30 (95% CI 0.20-0.40) for the Phe cutoff value of 1200 ± 200 µmol/L.
Conclusions:
Substantial regional variation in the birth prevalence of PAH deficiency was observed in this systematic literature review and meta-analysis of published evidence from newborn screening. The precision of the prevalence estimates is limited by relatively small sample sizes, despite widespread and longstanding newborn screening in much of the world.
More Related Videos
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
Related Concept Videos
Inborn Errors of Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pedigree Analysis
Pharmacokinetics in Pediatric Patients: Drug Distribution
Probability Laws